Sharekhan

Panacea Biotec Ltd

Wed 30/07/2025,15:59:53 NSE: PANACEABIO

₹ 412.30 -12.35 (-2.91%)
BUY NOW Buy Panacea Biotec Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Panacea Biotec Ltd

Wed 30/07/2025,16:1:0

Panacea Biotec Ltd

Wed 30/07/2025,15:59:53 | NSE : PANACEABIO

₹ 412.30-12.35 (-2.91%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 424.90

Previous Close

₹ 424.65

Volume

234159

Mkt Cap ( Rs. Cr)

₹2525.37

High

₹ 426.80

Low

₹ 409.60

52 Week High

₹ 581.90

52 Week Low

₹ 131.76

Book Value Per Share

₹ 135.98

Dividend Yield

0.00

Face Value

₹ 1.00

What’s Your Call?

Collective community sentiment on Panacea Biotec Ltd

Your Vote -

Buy

92.82%

Hold

3.31%

Sell

3.87%

92.82%

181 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

412.30

52

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

52

Option Chain

Analyzes market sentiment, predicts Panacea Biotec Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Panacea Biotec L - Intimation Under Regulation 30 And Regulation 31A(8) Of The Securities & Exchange Board Of India (Listing

    29 Jul 2025, 5:43PM We are pleased to inform that the Company has received on July 29, 2025, the requisite approval from BSE and NSE for reclassification from \Promoter a

  • Panacea Biotec L - Copy of Newspaper Publication

    19 Jul 2025, 3:11PM Panacea Biotec Limited has informed the Exchange about Copy of Newspaper Publication regarding Notice intimating the shareholders about the opening of

  • Panacea Biotec L has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2025

    19 Jul 2025, 7:03AM As of June 2025, 72.48% is owned by Indian Promoters and 27.52% by Public. <p align=justify> Top five Promoters holding highest number of shares of Pa

  • Panacea Biotec L - Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

    11 Jul 2025, 4:56PM Panacea Biotec Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

  • Panacea Biotec L - Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

    9 Jul 2025, 3:15PM Panacea Biotec Limited has informed the Exchange about Settlement of Disputes with Apotex Inc., Canada

  • Panacea Biotec L - Intimation Of Settlement Of Disputes With Apotex Inc., Canada\r\nUnder Regulation 30 Of SEBI (Listing Obli

    9 Jul 2025, 3:20PM We are pleased to inform you that the parties have executed a Settlement Agreement on July 09, 2025, recording full and final settlement of the disput

  • Panacea Biotec L - Updates

    7 Jul 2025, 4:30PM Panacea Biotec Limited has informed the Exchange regarding 'Reporting of violations of Company's Code of Conduct under SEBI (Prohibition ofInsider Tra

  • Panacea Biotec L - Updates

    7 Jul 2025, 4:13PM Panacea Biotec Limited has informed the Exchange regarding 'Details of Shares dematerialized during June 2025 under Regulation 74(5) of the SEBI (Depo

  • Panacea Biotec L - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    7 Jul 2025, 4:08PM Panacea Biotec Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

  • Panacea Biotec L - Details Of Shares Dematerialised During June 2025 Under Regulation 74(5) Of The SEBI (Depositories And Pa

    7 Jul 2025, 4:44PM We would like to inform you that no share has been dematerialised during the month of June, 2025. \r\n\r\nA copy of the certificate from the Company's

  • Panacea Biotec L - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    7 Jul 2025, 4:40PM We are enclosing a certificate dated July 02, 2025, issued by Skyline Financial Services Private Limited, Registrar and Transfer Agent of the Company,

  • Panacea Biotec L - Disclosure under SEBI Takeover Regulations

    27 Jun 2025, 5:48PM ÿSandeep Jainÿhas Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acq

  • Panacea Biotec L - Trading Window-XBRL

    26 Jun 2025, 5:16PM Panacea Biotec Limited has informed the Exchange about Closure of Trading Window

  • Panacea Biotec L - Trading Window

    26 Jun 2025, 5:15PM Panacea Biotec Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2

  • Panacea Biotec L - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    3 Jun 2025, 11:20AM Please find attached Press Release regarding inclusion of EmulsiPan adjuvant in the CEPI Adjuvant Library and its foray into commercialisation of its

  • Panacea Biotec L - Press Release

    3 Jun 2025, 11:15AM Panacea Biotec Limited has informed the Exchange regarding a press release dated Jun 03, 2025, titled ""Press Release - Inclusion of EmulsiPan adjuvan

  • Panacea Biotec L - Copy of Newspaper Publication

    31 May 2025, 2:58PM Panacea Biotec Limited has informed the Exchange about Copy of Newspaper Publication of Extract of Statement of Audited Standalone and Consolidated Fi

  • Panacea Biotec L - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    30 May 2025, 8:40PM PANACEA BIOTEC LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agen

  • Panacea Biotec L - Updates

    30 May 2025, 8:39PM Panacea Biotec Limited has informed the Exchange regarding 'Appointment of Secretarial Auditor for 5 consecutive years'.

  • Panacea Biotec L - Intimation Regarding Appointment Of Secretarial Auditor

    30 May 2025, 8:37PM M/s R&D Company Secretaries have been appointed as Secretarial Auditors for a period of 5 consecutive years commencing from FY 2025-26 to FY 2029-30

  • Panacea Biotec L posts Q4 net loss of Rs 12.39 cr

    30 May 2025, 8:26PM The company reported standalone net loss during the quarter stood at Rs 12.39 crore as compared to net loss of Rs 1.37 crore in the previous year quar

  • Panacea Biotec L - Standalone And Consolidated Audited Financial Results Along With Auditors' Report For The Quarter And Fina

    30 May 2025, 8:22PM The Standalone and Consolidated financial results for quarter and financial year ended March 31, 2025 is attached herewith.

  • Panacea Biotec L - Outcome of Board Meeting

    30 May 2025, 8:14PM Panacea Biotec Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.

  • Panacea Biotec L - Outcome of Board Meeting

    30 May 2025, 8:07PM Panacea Biotec Limited has informed the Exchange regarding outcome of Board meeting held on May 30, 2025.

  • Panacea Biotec L - Board Meeting Outcome for 1. Standalone And Consolidated Audited Financial Results Along With Auditors' Re

    30 May 2025, 8:06PM Please find attached Outcome of Board Meeting held on May 30, 2025.

  • Panacea Biotec L - Board Meeting Intimation

    24 May 2025, 3:39PM PANACEA BIOTEC LIMITED has informed the Exchange about Board Meeting to be held on 30-May-2025 to consider and approve the Yearly Audited Financial re

  • Panacea Biotec L - Board Meeting Intimation for For Approval Of The Audited Financial Results For The Quarter And Financial Y

    24 May 2025, 3:36PM Panacea Biotec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 ,inter alia, to consider and a

  • Panacea Biotec L - Updates

    19 May 2025, 5:47PM Panacea Biotec Limited has informed the Exchange regarding 'Nation-Wide Study Confirms ChilRun full Accelerates Growth and Development in Children, in

  • Panacea Biotec L - Nation-Wide Study Undertaken By Panacea Biotec Pharma Ltd. (Material WOS) Confirms Chilrun Full Accelerate

    19 May 2025, 5:49PM A copy of the Nation-Wide Study undertaken by Panacea Biotec Pharma Ltd. (material WOS) confirms ChilRun full Accelerates Growth and Development in Ch

  • Panacea Biotec L - Updates

    6 May 2025, 4:49PM Panacea Biotec Limited has informed the Exchange regarding 'Details of Shares dematerialized during April 2025'.

  • Panacea Biotec L - Details Of Shares Dematerialized During April 2025 Under Regulation 74(5) Of The SEBI (Depositories And Pa

    6 May 2025, 4:49PM Please find attached details of shares dematerialised during April, 2025 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulation

  • Panacea Biotec gains on Rs. 127 crore contract from UNICEF

    26 Dec 2024 , 10:36AM Receives LoA from UNICEF for supply of bivalent oral polio vaccine

  • Panacea Biotec

    17 Sep 2024 , 11:01AM Panacea Biotec announced that it has reached a settlement with Sanofi Healthcare India Pvt.

  • Panacea Biotec launches Paclitaxel Protein-Bound Particles for Injectable Suspension

    28 Oct 2023 , 5:19PM Launch of Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound), a generic version of Abraxane

  • Panacea Biotec launches Paclitaxel Protein-Bound Particles for Injectable Suspension

    28 Oct 2023 , 5:08PM Launch of Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound), a generic version of Abraxane

  • Panacea Bio introduces Food & Nutritional Products

    15 Jun 2023 , 11:05AM Panacea Bio arm launches new range of paediatric food & nutritional products in India

  • Panacea Biotec

    11 Oct 2022 , 11:09AM The company has received long-term supply contract worth $127.30 million (around Rs. 1,040 Crore) from UNICEF and Pan American Health Organization (PAHO) for supply of its WHO pre-qualified fully liquid Pentavalent vaccine, Easyfive-TT (DTwP-HepB-Hib). EasyFive-TT is a ready-to-use combination vaccine that does not require preparation by healthcare workers at the clinic, reduces the number of visits to vaccination centres, and reduces the overall cost of immunisation for all stakeholders. The vaccine protects children against five deadly diseases: Diphtheria, Tetanus, Pertussis, Hepatitis B and invasive infections caused by Haemophilus Influenza Type b. Easyfive-TT was launched in India in 2005. After receiving WHO prequalification in 2008, more than 150 million doses have been supplied to over 75 countries globally.

  • Panacea Biotec up 9% on first shipment of second component of Sputnik V

    7 Sep 2021 , 12:31PM Panacea Biotec supplies 1st shipment of the second component of Sputnik V vaccine produced in India

  • Panacea Biotec up 9% on first shipment of second component of Sputnik V

    7 Sep 2021 , 12:31PM Panacea Biotec supplies 1st shipment of the second component of Sputnik V vaccine produced in India

  • Panacea Biotec receives licence to produce Sputnik V vaccine at Himachal Pradesh

    5 Jul 2021 , 10:21AM Panacea Biotec announces receipt of manufacturing license to produce Sputnik V vaccine at Baddi, Himachal Pradesh

  • Panacea Biotech

    5 Jul 2021 , 9:35AM Has received manufacturing license from Drugs Controller General (India) for Sputnik V vaccine against Covid-19 pursuant to its collaboration with Russian Direct Investment Fund. The license is a necessary condition for using Sputnik V produced by Panacea Biotec in India. The batches produced at Panacea’s plant have been earliet shipped to Russia and have cleared by all the checks for quality parameters. The vaccine has been registered with 67 countries and the receipt of the license from the DCGI is positive.

  • Panacea Biotec to consider fund raising plan

    28 May 2021 , 10:03AM Board to meet on June 02, for fund raising

  • RDIF, Panacea Biotec launch the production of Sputnik V in India

    24 May 2021 , 4:14PM Panacea Biotec now to produce 100 million doses of Sputnik V per year

  • Panacea Biotec to produce 100 million doses of Sputnik V

    6 Apr 2021 , 11:19AM RDIF, Panacea Biotec agree to produce 100 million doses of Sputnik V vaccine in India per year

  • Panacea Biotec

    6 Apr 2021 , 9:41AM Panacea Biotec: Has signed an agreement with the Russian Direct Investment Fund (RDIF) to produce 100 million doses per year of Sputnik V vaccine in India. Production of these vaccines at Panacea Biotec sites will enable RDIF to meet the global supply to international partners. Positive for RDIF

  • Panacea Biotec announces successful completion of Phase I/II

    24 Sep 2020 , 12:12PM Panacea Biotec announces successful completion of Phase 1/11 study of its novel

  • Panacea Biotec collaborates with Refana for Covid-19 vaccine

    10 Jun 2020 , 10:54AM Panacea Biotec and Refana announce landmark collaboration for Covid-19 vaccine

  • Panacea up on signing agreement with Serum Institute

    18 Jan 2018 , 12:21PM Panacea Biotec surges over 10% at Rs283.70, after signing two long term agreements with Serum Institute of India and its subsidiary

  • Panacea surges on getting USFDA approval

    24 Oct 2017 , 2:38PM Panacea Biotech surges over 15% at Rs275.9, after US drug regulator approves Abbreviated New Drug Application (ANDA) for Prasugrel 5 mg and 10 mg tablets

  • Panacea Biotec expands collaboration with US firm

    11 Sep 2017 , 2:26PM Panacea Biotec expands its existing collaboration with Apotex Inc for sales & distribution of Prasugrel 5mg and 10mg tablets
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Panacea Biotec Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 542.42 454.009 428.102 499.249 570.247
Liabilities 542.42 454.009 428.102 499.249 570.247
Equity 6.13 6.125 6.125 6.125 6.125
Gross Profit -6.93 14.167 -62.627 -72.67 0.488
Net Profit -15.23 3.55 -87.544 -93.576 -14.441
Cash From Operating Activities 3.94 37.273 -10.742 -52.69 38.266
NPM(%) -4.91 0.98 -34.05 -39.73 -4.2
Revenue 309.85 359.604 257.067 235.504 343.555
Expenses 316.78 345.437 319.694 308.174 343.067
ROE(%) -1.82 0.42 -10.51 -11.23 -1.73

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
19 Sep 2011 0.75 75 0 184.8
16 Sep 2010 0.25 25 0 225.1
19 Sep 2008 1 100 0 301.55
21 Sep 2007 1 100 0 424.4
22 Sep 2006 1 100 0 358.15
12 Aug 2005 1.5 150 0 144.8
13 Sep 2004 1 100 0 45.1
12 Sep 2003 1 100 0 34.5
13 Aug 2002 0 100 0 365.8
0 0 0 360.4
07 Aug 2001 0 100 0 473
0 50 0 391.2
0 50 0 224
0 30 0 105.7

Peers

Other companies within the same industry or sector that are comparable to Panacea Biotec Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 895.40 -1.33 29.71 235.56 301.39 0.56
Lotus Eye Hospital and Institute Ltd 72.74 -1.49 207.83 858.37 3.55 0.00
Vaishali Pharma Ltd 12.43 0.89 207.17 442.44 3.13 0.00
Astec Lifesciences Ltd 864.50 -0.98 0.00 809.46 -601.21 0.00

Company Info

YEAR EVENTS 1984 - Panacea Biotec Ltd. was incorporated as a private limited company in the name and style of Panacea Drugs Private Ltd. on 2nd February. Subsequently the Company became deemed Public limited Company u/s 43A(1 A) of the Companies Act, 1956 w.e.f. 30.6.93. - The Company is engaged in 4 product lines of Pharmaceuticals are Vaccines, Biologicals, formulations, Natural Products. - The Company has been promoted by Mr. Sosh, Kumar Jain, who is a pharmacist having about 40 years of experience in the pharmaceutical industry. 1993 - The name of the Company changed to Panacea Biotec Limited on 7th September. - The Company now proposes to expand the capacity of Vaccines Division, along with an expansion in the capacities of capsules and suspensions. 1994 - The Company is using technology developed in-house and is not entering into any technical collaboration as it has adequate technical expertise. 1995 - During the year the company is public issue of 21,28,000 No. of Equity Shares of Rs. 10/- each for cash at a premiumof Rs. 50/- per share aggregating Rs. 1276/80 Lacs, and reservation of 6,72,000 No. of Equity Shares of Rs. 10/- each for cash at a premium of Rs. 50/- per share aggregating Rs. 4,03,20,000 for firm allotment to NRIs/OCB's. 1996 - The Company has successfully commissioned a state-of-the-art Viral Vaccine Research facility at Latru near Chandigarh. 1997 - Panacea Biotec (PBL) has been going global with a gusto. It has introduced some speciality formulations like Nimulid and, two of these are under worldwide patent in PBL's name with applications filed in 72 countries. 1999 - During the year under review, the Company had allotted 50,00,000 - 12% Redeemable Cumulative Preference Shares of Rs.10/- each aggregating Rs.5.00 Crores to Industrial Development Bank of India on private placement basis. 2000 - Panacea Biotech Ltd, a pharmaceutical company in North India, is exploring opportunities for growth through expansion, diversification and backward integration. - The company has proposed an amendment in articles of association for implementing the depository system for its stocks. - The company's various product introductions like Nimulid, Livoluc, Nimulid gel, Risipid etc have been well received in the market. - Panacea Biotec Ltd (PBL) has entered into a joint venture with Heber Biotec Ltd (HBL) of Cuba to manufacture Hepatitis-B vaccine in bulk form. A new company - Pan Heber Biotec Ltd - has been formed for the purpose in which the two partners hold equal stake. - The company is setting up another plant at Lalru to manufacture branded formulations for the export market. - The company is planning to launch an anti-histamine drug in June this year. - Panacea Biotech has set up two wholly-owned subsidiary companies in the UK and Hong Kong with the objective of importing and exporting pharmaceutical, technology and other products. - The Company has entered into agreement with NSDL and CDSL for dematerialisation. 2001 - Panacea Biotec Ltd (PBL), a Delhi-based pharma company, has recently signed an agreement with National Research Development Corporation (NRDC) to commercialise the know-how for an opthalmic formulation of ocular delivery, using nanotechnology. 2002 -Appoints Mr Rajesh Jain and Mr Sandeep Jain as the Joint Managing Directors of the company. -Files for worldwide patent for its new NDDS for an anti-TB combination drug. -Board approves for the subdivision of shares from Rs.10 per share of Re.1 per share , and also decides to wind up the company's wholly owned subsidiary at Isle of Man, UK. -Company's non-executive director makes a gift of 2,01,000 shares of Re.1 each representing 0.35% of the company's total capital. -Commences marketing of herbal and dietary supplement products under its SBU viz. "Best on Health" and launches ThankGod capsules, ThankGod Anytime cream, ThankGod pain & Itch relief cream etc. 2003 -Stock split from Rs 10 per equity share to Rs 1 per equity share - Panacea Biotec forays OTC market with Herbal Products 2004 -California-based Chiron Vaccines, the world's 5th largest vaccine producer, has struck a deal with Delhi-based Panacea Biotec to set up a joint venture in India -Panacea Biotec launches new product HEARTFELT, natural therapy for cholesterol management developed by its Research & Development Team. -Panacea rolls out new nimesulide injection -Launches Combination vaccines through JV with Chiron Vaccines, UK on November 24, 2004 2005 -Panacea Biotec launches 'Upright' for effective relief from severe pain & inflammation -Panacea Biotec introduces Noval Anti-allergy Drug - Ralif 2006 -Panacea Biotec enters into an agreement with PT Bio Farma to manufacture Measles Vaccine 2007 - Panacea Biotec signs agreement with Family Vaccines to supply combination vaccines 2009 - Panacea Biotec - EasyFive Injects; USD 222.37 million Award by UNICEF 2010 - Panacea Biotech's Baddi unit gets US FDA approval - Panacea Bio - Board recommends Dividend of Re. 0.25 (25%) each on Equity Shares of the Company, for the financial year 2009-10. 2011 - PanaceBiotec - Panacea Biotec Launches - PacliALL - Panacea Biotec announced that the company is mulling to foray into healthcare infrastructure sector with setting up of multi specialty hospital in Gurgaon, Haryana. 2012 - PanaceBiotec - Panacea Biotec celebrates 63rd Indian Republic day with launch of "POLPROTEC" in Nigeria". - Panacea Biotech launches Inactivated Polio Virus vaccine in Nigeria - PanaceBiotec - Panacea Biotec inaugurates state of the art Oncology Production Unit - PanaceBiotec - Panacea Biotec Entered into Strategic Alliance with Osmotica Pharmaceutical - Panacea Biotec wins order worth Rs 187 cr from Govt to supply polio vaccines 2013 -Panacea Biotec Ltd has opened up its wholly owned subsidiary in UAE in the name of Panol Industries. 2014 -Panacea Biotec Ltd has entered into collaboration with a leading International Pharmaceutical Company for the development and supply of an immunosuppressant generic product in USA. - "Panacea Biotec Announces Collaboration with Rising Pharmaceuticals Inc.". -Company has received UNICEF Award for supply of Companys DTB-HebB-Hib (Pentavalent) Vaccine Easyfive-TT to UNICEF. 2015 -Panacea Biotec Gets Pan American Health Organization (PAHO) order for supply of EasyFive-TT Vaccines worth 2016 -"Panacea Biotec Launches - CABAPAN, A Cost Effective product for the treatment of metastatic Castration Resistant Prostrate Cancer (mCRPC)". -Panacea Biotec Receives Prestigious Intellectual Property & Science Award "Top 50 Indian Innovators 2015"". -Panacea Biotec Launches - TENEPAN, a cost effective product for the treatment of Type 2 Diabetes Mellitus (T2DM)". -"Panacea Biotec Introduces World's First Fully Liquid Tetravalent Vaccine Easyfour-TT against DTP and Hib". 2017 -Panacea Biotec Introduces World's First Fully Liquid Hexavalent Combination Vaccine EasySixTM for Six Preventable Diseases. -Panacea Biotec announces ANDA approval for US Market and LTA & Award from UN Agencies for Supply of Pentavalent Vaccine (Easyfive-TT). -Panacea Biotec Announces Joint Collaboration with Bionpharma Inc. 2018 -Panacea Biotec inks Tripartite Agreement with Natco Pharma Ltd. and Breckenridge Pharmaceutical Inc. for manufacturing and supply of Azacitidine injection in the U.S. Market. 2019 -Panacea Biotec Announces Launch Of ViLACT For Treatment Of Uncontrolled Type 2 Diabetes Mellitus Patients. -Panacea Biotec receives USD 24.32 Million Award of Pentavalent Vaccine from U.N. Agencies. 2021 -RDIF and Panacea Biotec launch the production of Sputnik V in India. -Panacea Biotec supplies 1st shipment of the second component of Sputnik V vaccine produced in India. 2022 -Panacea Biotec receives UNICEF & PAHO awards for supply of Pentavalent Vaccine.. -CEPI, THSTI and Panacea Biotec partner to develop broadly protective Betacoronavirus vaccines. 2023 -Panacea Biotec launches EasyFourPol in India and receives registration of Valganciclovir Powder for Oral Solution in Germany. - Panacea Biotec Launches Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound), a genericversion of Abraxane. -Launch of new range of high-quality pediatric food & nutritional products in India by Company's wholly owned subsidiary, Panacea Biotec Pharma Limited '. 2024 -The Company has received a Letter of Award from UNICEF for supply of 115 million doses of its bivalent oral polio vaccine (bOPV) worth US$ 14.95 million.

YEAR EVENTS 1984 - Panacea Biotec Ltd. was incorporated as a private limited company in the name and style of Panacea Drugs Private Ltd. on 2nd February. Subsequently the Company became deemed Public limited Company u/s 43A(1 A) of the Companies Act, 1956 w.e.f. 30.6.93. - The Company is engaged in 4 product lines of Pharmaceuticals are Vaccines, Biologicals, formulations, Natural Products. - The Company has been promoted by Mr. Sosh, Kumar Jain, who is a pharmacist having about 40 years of experience in the pharmaceutical industry. 1993 - The name of the Company changed to Panacea Biotec Limited on 7th September. - The Company now proposes to expand the capacity of Vaccines Division, along with an expansion in the capacities of capsules and suspensions. 1994 - The Company is using technology developed in-house and is not entering into any technical collaboration as it has adequate technical expertise. 1995 - During the year the company is public issue of 21,28,000 No. of Equity Shares of Rs. 10/- each for cash at a premiumof Rs. 50/- per share aggregating Rs. 1276/80 Lacs, and reservation of 6,72,000 No. of Equity Shares of Rs. 10/- each for cash at a premium of Rs. 50/- per share aggregating Rs. 4,03,20,000 for firm allotment to NRIs/OCB's. 1996 - The Company has successfully commissioned a state-of-the-art Viral Vaccine Research facility at Latru near Chandigarh. 1997 - Panacea Biotec (PBL) has been going global with a gusto. It has introduced some speciality formulations like Nimulid and, two of these are under worldwide patent in PBL's name with applications filed in 72 countries. 1999 - During the year under review, the Company had allotted 50,00,000 - 12% Redeemable Cumulative Preference Shares of Rs.10/- each aggregating Rs.5.00 Crores to Industrial Development Bank of India on private placement basis. 2000 - Panacea Biotech Ltd, a pharmaceutical company in North India, is exploring opportunities for growth through expansion, diversification and backward integration. - The company has proposed an amendment in articles of association for implementing the depository system for its stocks. - The company's various product introductions like Nimulid, Livoluc, Nimulid gel, Risipid etc have been well received in the market. - Panacea Biotec Ltd (PBL) has entered into a joint venture with Heber Biotec Ltd (HBL) of Cuba to manufacture Hepatitis-B vaccine in bulk form. A new company - Pan Heber Biotec Ltd - has been formed for the purpose in which the two partners hold equal stake. - The company is setting up another plant at Lalru to manufacture branded formulations for the export market. - The company is planning to launch an anti-histamine drug in June this year. - Panacea Biotech has set up two wholly-owned subsidiary companies in the UK and Hong Kong with the objective of importing and exporting pharmaceutical, technology and other products. - The Company has entered into agreement with NSDL and CDSL for dematerialisation. 2001 - Panacea Biotec Ltd (PBL), a Delhi-based pharma company, has recently signed an agreement with National Research Development Corporation (NRDC) to commercialise the know-how for an opthalmic formulation of ocular delivery, using nanotechnology. 2002 -Appoints Mr Rajesh Jain and Mr Sandeep Jain as the Joint Managing Directors of the company. -Files for worldwide patent for its new NDDS for an anti-TB combination drug. -Board approves for the subdivision of shares from Rs.10 per share of Re.1 per share , and also decides to wind up the company's wholly owned subsidiary at Isle of Man, UK. -Company's non-executive director makes a gift of 2,01,000 shares of Re.1 each representing 0.35% of the company's total capital. -Commences marketing of herbal and dietary supplement products under its SBU viz. "Best on Health" and launches ThankGod capsules, ThankGod Anytime cream, ThankGod pain & Itch relief cream etc. 2003 -Stock split from Rs 10 per equity share to Rs 1 per equity share - Panacea Biotec forays OTC market with Herbal Products 2004 -California-based Chiron Vaccines, the world's 5th largest vaccine producer, has struck a deal with Delhi-based Panacea Biotec to set up a joint venture in India -Panacea Biotec launches new product HEARTFELT, natural therapy for cholesterol management developed by its Research & Development Team. -Panacea rolls out new nimesulide injection -Launches Combination vaccines through JV with Chiron Vaccines, UK on November 24, 2004 2005 -Panacea Biotec launches 'Upright' for effective relief from severe pain & inflammation -Panacea Biotec introduces Noval Anti-allergy Drug - Ralif 2006 -Panacea Biotec enters into an agreement with PT Bio Farma to manufacture Measles Vaccine 2007 - Panacea Biotec signs agreement with Family Vaccines to supply combination vaccines 2009 - Panacea Biotec - EasyFive Injects; USD 222.37 million Award by UNICEF 2010 - Panacea Biotech's Baddi unit gets US FDA approval - Panacea Bio - Board recommends Dividend of Re. 0.25 (25%) each on Equity Shares of the Company, for the financial year 2009-10. 2011 - PanaceBiotec - Panacea Biotec Launches - PacliALL - Panacea Biotec announced that the company is mulling to foray into healthcare infrastructure sector with setting up of multi specialty hospital in Gurgaon, Haryana. 2012 - PanaceBiotec - Panacea Biotec celebrates 63rd Indian Republic day with launch of "POLPROTEC" in Nigeria". - Panacea Biotech launches Inactivated Polio Virus vaccine in Nigeria - PanaceBiotec - Panacea Biotec inaugurates state of the art Oncology Production Unit - PanaceBiotec - Panacea Biotec Entered into Strategic Alliance with Osmotica Pharmaceutical - Panacea Biotec wins order worth Rs 187 cr from Govt to supply polio vaccines 2013 -Panacea Biotec Ltd has opened up its wholly owned subsidiary in UAE in the name of Panol Industries. 2014 -Panacea Biotec Ltd has entered into collaboration with a leading International Pharmaceutical Company for the development and supply of an immunosuppressant generic product in USA. - "Panacea Biotec Announces Collaboration with Rising Pharmaceuticals Inc.". -Company has received UNICEF Award for supply of Companys DTB-HebB-Hib (Pentavalent) Vaccine Easyfive-TT to UNICEF. 2015 -Panacea Biotec Gets Pan American Health Organization (PAHO) order for supply of EasyFive-TT Vaccines worth 2016 -"Panacea Biotec Launches - CABAPAN, A Cost Effective product for the treatment of metastatic Castration Resistant Prostrate Cancer (mCRPC)". -Panacea Biotec Receives Prestigious Intellectual Property & Science Award "Top 50 Indian Innovators 2015"". -Panacea Biotec Launches - TENEPAN, a cost effective product for the treatment of Type 2 Diabetes Mellitus (T2DM)". -"Panacea Biotec Introduces World's First Fully Liquid Tetravalent Vaccine Easyfour-TT against DTP and Hib". 2017 -Panacea Biotec Introduces World's First Fully Liquid Hexavalent Combination Vaccine EasySixTM for Six Preventable Diseases. -Panacea Biotec announces ANDA approval for US Market and LTA & Award from UN Agencies for Supply of Pentavalent Vaccine (Easyfive-TT). -Panacea Biotec Announces Joint Collaboration with Bionpharma Inc. 2018 -Panacea Biotec inks Tripartite Agreement with Natco Pharma Ltd. and Breckenridge Pharmaceutical Inc. for manufacturing and supply of Azacitidine injection in the U.S. Market. 2019 -Panacea Biotec Announces Launch Of ViLACT For Treatment Of Uncontrolled Type 2 Diabetes Mellitus Patients. -Panacea Biotec receives USD 24.32 Million Award of Pentavalent Vaccine from U.N. Agencies. 2021 -RDIF and Panacea Biotec launch the production of Sputnik V in India. -Panacea Biotec supplies 1st shipment of the second component of Sputnik V vaccine produced in India. 2022 -Panacea Biotec receives UNICEF & PAHO awards for supply of Pentavalent Vaccine.. -CEPI, THSTI and Panacea Biotec partner to develop broadly protective Betacoronavirus vaccines. 2023 -Panacea Biotec launches EasyFourPol in India and receives registration of Valganciclovir Powder for Oral Solution in Germany. - Panacea Biotec Launches Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound), a genericversion of Abraxane. -Launch of new range of high-quality pediatric food & nutritional products in India by Company's wholly owned subsidiary, Panacea Biotec Pharma Limited '. 2024 -The Company has received a Letter of Award from UNICEF for supply of 115 million doses of its bivalent oral polio vaccine (bOPV) worth US$ 14.95 million.

Read More

Parent Organisation

Panacea Biotec Ltd.

Founded

02/02/1984

Managing Director

Dr.Rajesh Jain

NSE Symbol

PANACEABIOEQ

FAQ

The current price of Panacea Biotec Ltd is ₹ 412.30.

The 52-week high for Panacea Biotec Ltd is ₹ 426.80 and the 52-week low is ₹ 409.60.

The market capitalization of Panacea Biotec Ltd is currently ₹ 2525.37. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Panacea Biotec Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Panacea Biotec Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Panacea Biotec Ltd shares.

The CEO of Panacea Biotec Ltd is Dr.Rajesh Jain, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT